Skip to search formSkip to main contentSkip to account menu

PD 166326

Known as: PD166326 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Imatinib is used to treat chronic myelogenous leukemia (CML), but resistance develops in all phases of this disease. The purpose… 
Review
2007
Review
2007
Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality… 
2007
2007
Imatinib targets the Bcr-Abl oncogene that causes chronic myelogenous leukemia (CML) in humans. Recently, we demonstrated that… 
Highly Cited
2006
Highly Cited
2006
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukemia… 
Highly Cited
2005
Highly Cited
2005
Imatinib mesylate is highly effective in newly diagnosed chronic myeloid leukemia (CML), but BCR/ABL (breakpoint cluster region… 
Highly Cited
2005
Highly Cited
2005
In Philadelphia-positive (Ph(+)) leukemia, point mutations within the Bcr-Abl kinase domain emerged as a major mechanism of… 
Review
2003
Review
2003
The chronological history of the important discoveries leading to our present understanding of the essential clinical, biological… 
Highly Cited
2003
Highly Cited
2003
Inhibition of the constitutively active Bcr-abl tyrosine kinase(TK) by STI571 has proven to be a highly effective treatment for… 
Highly Cited
2003
Highly Cited
2003
Imatinib mesylate (STI571, Glivec), a 2-phenylaminopyrimidine small-molecule ATP competitor-type kinase inhibitor, proved to be… 
Highly Cited
2002
Highly Cited
2002
The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl. Imatinib mesylate (also known as…